{"id":"W4403420001","doi":"10.1016/j.jtho.2024.09.065","title":"OA12.03 Osimertinib After Definitive CRT in Unresectable Stage III EGFR-mutated NSCLC: Safety Outcomes from the Phase 3 LAURA Study","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Osimertinib; Medicine; Oncology; Internal medicine; Stage (stratigraphy); Epidermal growth factor receptor; Cancer; Erlotinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001653471,0.0006863532,0.001379661,0.0002202268,0.000304129,0.001576876,0.0005431152,0.0007359886,0.003314662],"category_scores_gemma":[0.001485046,0.0002094667,0.002089162,0.0003748365,0.0004877019,0.000962307,0.0003669175,0.002353307,0.0009536466],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008755982,"about_ca_system_score_gemma":0.0009202202,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001014693,"about_ca_topic_score_gemma":0.004388685,"domain_scores_codex":[0.9995062,0.0002161947,0.00002763521,0.00007647985,0.00005295463,0.0001204845],"domain_scores_gemma":[0.9991685,0.0001952653,0.0002515754,0.0001082442,0.00006828202,0.0002081792],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5726124,0.006866077,0.03250472,0.002033159,0.005435673,0.0002685811,0.0003267768,0.00538614,0.01384109,0.0009754882,0.0208366,0.3389133],"study_design_scores_gemma":[0.421135,0.3408784,0.1812117,0.0009618813,0.007252235,0.001270277,0.0005727781,0.006752787,0.006516615,0.002676026,0.03055234,0.0002199498],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.97694,0.01006894,0.0007114247,0.0009341697,0.0002403658,0.0004162715,0.003330895,0.0001525171,0.007205434],"genre_scores_gemma":[0.9857391,0.003297472,0.0006286395,0.0016675,0.0001919291,0.0004054993,0.004574831,0.00007172353,0.003423379],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003314662,"threshold_uncertainty_score":0.01108867,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03484657134441829,"score_gpt":0.4750201565719328,"score_spread":0.4401735852275145,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}